Trial record 1 of 1 for:
Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03747120 |
|
Recruitment Status :
Recruiting
First Posted : November 20, 2018
Last Update Posted : January 15, 2021
|
Sponsor:
Cedars-Sinai Medical Center
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Heather McArthur, Cedars-Sinai Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | July 2022 |
| Estimated Study Completion Date : | July 2023 |